Share your opinion and earn yourself a free Motley Fool premium report!

We are looking for Fools to join a 75 minute online independent market research forum on 15th / 16th December.

To find out more and express your interest please click here

Have £5,000 to invest? I’d buy these 2 FTSE 100 growth stocks

These FTSE 100 growth stocks are beating the market. Roland Head explains why he expects these big-cap winners to deliver further gains.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 is often associated with huge, mature businesses that pay dividends but deliver very little growth. Today I want to get away from that cliché and look at two terrific growth stocks that have made it into the blue-chip index.

Both of my picks have delivered double-digit share price gains over the last two years — the FTSE 100 has fallen by around 15% over the same period.

Growth stock #1: a pharma play

Hikma Pharmaceuticals (LSE: HIK) has been a top performer so far this year, rising by around 20% in five months. Although pharmaceutical firms have benefited from extra investor interest due to the coronavirus pandemic, I believe Hikma is a genuine growth stock, with solid profits and good prospects.

The group’s business is centred around producing injectable medicines and generic versions of branded products that have lost their patent protection. It’s a very profitable business, with an operating margin of 24% in 2019.

Cash generation is also strong and unlike some larger pharma groups, Hikma doesn’t rely on borrowed cash. Net debt was just $242m at the end of 2019, giving a leverage multiple of just 0.4x EBITDA. In plain English, that’s very low.

Why I’d buy

City forecasts suggest that Hikma’s profits will rise by around 8% this year, with a 10% increase pencilled in for 2021.

The firm’s shares are currently trading close to all-time highs, leaving them with a 2020 forecast price/earnings ratio of around 18. That may not seem cheap, but it’s actually well below the UK pharmaceutical sector average P/E of 30.

Profits are expected to rise by a further 10% in 2021. I see the firm as a growth stock to buy at current levels.

Growth stock #2: my bet on UK property

The UK housing market might not seem like the safest investment at the moment. But I think my next pick is an essential service that estate agents can’t live without — even in a downturn.

Property listing website Rightmove (LSE: RMV) dominates the UK market, leaving rivals Zoopla and OnTheMarket.com trailing in the distance. According to the firm, it had a market share of over 75% in 2019, based on the time spent browsing the top four UK property websites.

This dominance gives Rightmove a lot of pricing power. The company generated an operating profit of £214m on revenue of £289m last year. That’s equivalent to a profit margin of 74%. It’s not hard to see why this has been such a successful growth stock — the Rightmove share price has risen by nearly 40% over the last 18 months.

A long-term winner?

Estate agents tend to complain about Rightmove’s pricing. Some big estate agency groups even clubbed together to launch a rival, OnTheMarket.com.

I have some sympathy with the estate agents’ complaints. But Rightmove is expanding steadily into the letting sector and now also lists new homes. In reality, I believe this website will continue to be an essential part of most estate agents’ businesses.

Rightmove has cut its fees by 75% for the period from April to July this year. 2020 profits will be down. But analysts expect earnings to bounce back next year — a view I share.

The latest forecasts put Rightmove stock on a price/earnings ratio of 30 for 2021. For such a dominant and profitable business, I think this could be a good buy.

Roland Head has no position in any of the shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals and Rightmove. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Businessman hand flipping wooden block cube from 2024 to 2025 on coins
Investing Articles

After huge gains for S&P 500 tech stocks in 2025, here are 4 moves I’m making to protect my ISA and SIPP

Gains from S&P tech stocks have boosted Edward Sheldon’s retirement accounts this year. Here’s what he’s doing now to reduce…

Read more »

View of Lake District. English countryside with fields in the foreground and a lake and hills behind.
Investing Articles

With a 3.2% yield, has the FTSE 100 become a wasteland for passive income investors?

With dividend yields where they are at the moment, should passive income investors take a look at the bond market…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Should I add this dynamic FTSE 250 newcomer to my Stocks and Shares ISA?

At first sight, a UK bank that’s joining the FTSE 250 isn’t anything to get excited by. But beneath the…

Read more »

Investing Articles

£10,000 invested in BT shares 3 months ago is now worth

BT shares have been volatile lately and Harvey Jones is wondering whether now is a good time to buy the…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

After a 66% fall, this under-the-radar growth stock looks like brilliant value to me

Undervalued growth stocks can be outstanding investments. And Stephen Wright thinks he has one in a company analysts seem to…

Read more »

Content white businesswoman being congratulated by colleagues at her retirement party
Investing Articles

Don’t ‘save’ for retirement! Invest in dirt cheap UK shares to aim for a better lifestyle

Investing in high-quality and undervalued UK shares could deliver far better results when building wealth for retirement. Here's how.

Read more »

Black woman using smartphone at home, watching stock charts.
Investing Articles

1 growth and 1 income stock to kickstart a passive income stream

Diversification is key to achieving sustainable passive income. Mark Hartley details two broadly different stocks for beginners.

Read more »

ISA coins
Investing Articles

How to aim for a £12k second income starting with a 20k ISA

With inflation and taxes on the rise, having a tax-free second income is now more important than ever. Zaven Boyrazian…

Read more »